Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations, capital structure, and governance. This page brings together those SEC filings and pairs them with AI-powered tools to help readers interpret the information more efficiently.
For Amneal, current reports on Form 8-K are a key source of timely disclosures. Recent 8-K filings describe quarterly financial results, including net revenue trends across the Affordable Medicines, Specialty, and AvKARE segments, as well as updates to full-year guidance. Other 8-Ks outline significant financing transactions, such as new seven-year term B loans, senior secured notes due 2032, and amendments to the company’s revolving credit agreement, along with details on collateral, covenants, and maturity profiles.
Filings also cover governance and stockholder matters. For example, Amneal has reported preliminary financial results, changes to board composition when designation rights shifted under a stockholders agreement, and the board’s decision to hold Say-on-Pay advisory votes on an annual basis following stockholder preferences expressed at an annual meeting.
On this page, users can access Amneal’s Forms 8-K and, through links to its broader filing history, locate annual reports on Form 10-K and quarterly reports on Form 10-Q. These longer-form filings typically include segment discussions for Affordable Medicines, Specialty, and AvKARE, risk factor summaries, and explanations of non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS referenced in earnings releases.
AI features on the platform provide summaries and highlights of lengthy filings, helping readers identify key topics such as segment performance, debt structure, covenant changes, and governance decisions without reading every line. Users interested in AMRX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures, and better understand how regulatory documents reflect Amneal’s evolving business and capital structure.
Amneal Pharmaceuticals, Inc. Schedule 13D/A shows that Dipan Patel beneficially owns 23,828,992 shares of Class A common stock, representing 7.6% of the 314,079,309 shares outstanding used for the calculation. The filing states these shares are held of record by trusts controlled by the reporting person and that Patel has sole voting and dispositive power over the shares.
The amendment adds loan documentation: a trust controlled by Patel pledged 3,050,000 Class A shares as collateral under a promissory note and related agreements with Enterprise Bank & Trust. The loan matures on 11/05/2026, and customary foreclosure rights exist for the bank if events of default occur.
Amneal Pharmaceuticals director John Kiely reported a sale of Class A common stock on 08/27/2025. The Form 4 shows 32,000 shares were sold at a weighted-average price of $9.23 per share (prices ranged $9.20–$9.25). After the sale, the reporting person beneficially owned 225,433 shares, held directly. The filing was signed by an attorney-in-fact on 08/28/2025. The Form 4 discloses the transaction details and the footnote states the seller will provide a breakdown of shares sold at each price upon request.
Amneal Pharmaceuticals (AMRX) filed a Form 144 to notify a proposed sale of 32,000 Class A shares through Merrill Lynch (157 Church St, New Haven, CT) with an approximate sale date of 08/27/2025. The filing reports an aggregate market value of $293,810 for the shares and shows 314,079,309 shares outstanding for the class. The shares were acquired on 05/10/2024 as equity compensation from Amneal Pharmaceuticals, with payment recorded on the same date. The filer reports no sales in the past three months and provides the standard certification that no undisclosed material adverse information is known.
Insider sales by Amneal Pharmaceuticals officer. Nikita Shah, identified as Executive Vice President and reporting person, sold a total of 120,832 shares of Amneal Pharmaceuticals, Inc. (AMRX) in two transactions: 114,492 shares on 08/22/2025 at a weighted-average price of $9.66 and 6,340 shares on 08/25/2025 at a weighted-average price of $9.50. Following these disposals the filing shows beneficial ownership of 146,403 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025. The filing provides weighted-price ranges for the sales and offers to provide detailed per-transaction quantities on request.
Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported insider transactions executed on 08/20/2025. He exercised 175,000 stock options at a $2.75 exercise price, acquiring 175,000 Class A common shares. On the same date he sold 279,244 Class A common shares at a weighted average price of $9.38, with sale prices ranging from $9.30 to $9.40 per share.
After these transactions the Form 4 shows Mr. Boyer beneficially owned 431,670 Class A shares before the sale line and 152,426 Class A shares following the sale line, and held 97,480 options (derivative securities) after the reported option exercise. The filing was signed by an attorney-in-fact on 08/22/2025 and notes the exercised options were fully vested.
Amneal Pharmaceuticals (AMRX) Form 144 notice records a proposed sale of 36,796 Class A shares with an aggregate market value of $356,921, intended for sale on 08/22/2025 on NASDAQ. The filer reports the shares were acquired as equity compensation from Amneal Pharmaceuticals on 03/01/2023 (18,628 shares) and 03/03/2023 (18,168 shares). The filing also discloses three recent sales by the same person during August 2025 totaling 205,730 Class A shares for gross proceeds of $1,935, - [aggregate per rows: $818,930; $663,065; $453,000]. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and carries the required signature and warning about false statements.
Amneal Pharmaceuticals, Inc. (AMRX) Form 144 indicates a proposed sale of 84,036 common shares through Charles Schwab, with an aggregate market value of $818,930.82. The filing lists approximately 314,079,309 shares outstanding and an approximate sale date of 08/22/2025 on NASDAQ. The securities were acquired on 07/05/2018 as executive compensation. The filing also discloses two recent sales by the named person: 71,694 shares sold on 08/14/2025 for $666,037.26 and 50,000 shares sold on 08/12/2025 for $452,030.89. The signer represents they are not aware of any undisclosed material adverse information about the issuer.
Amneal Pharmaceuticals (AMRX) reported a Form 144 notice showing proposed sales by an affiliate. The filer intends to sell 175,000 Class A shares with an aggregate market value of $1,637,900, against approximately 314.08 million shares outstanding, with an approximate sale date of 08/20/2025 on NASDAQ. The filing records the shares were acquired as stock options on 05/07/2018 from Amneal Pharmaceuticals. The form also discloses prior sales in the past three months totaling 137,680 Class A shares for gross proceeds of $1,272,163 (sales on 08/12/2025 and 08/20/2025). The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for Amneal Pharmaceuticals, Inc. (AMRX) reports a proposed sale of 104,244 common shares with an aggregate market value of $969,469, to be effected approximately on 08/20/2025 on NASDAQ through Charles Schwab.
The filing shows those 104,244 shares were acquired as restricted stock awards on multiple dates between 02/27/2022 and 03/03/2024 and paid as equity compensation. The issuer's total outstanding shares are reported as 314,079,309. The filing also discloses a prior sale by an identified seller, Andrew Boyer, of 33,436 shares on 08/12/2025 for $302,694. The signer certifies no undisclosed material adverse information and includes the standard Rule 144 representations.
Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), reported the sale of 71,694 shares of Class A common stock on 08/14/2025 at a weighted-average price of $9.29 per share, with individual trade prices ranging from $9.16 to $9.41. After the reported dispositions, the reporting person beneficially owned 267,235 shares, held directly. The Form 4 was filed indicating the transaction type as a sale and includes an explanatory footnote that the reported price is a weighted average from multiple trades. The form is signed by an attorney-in-fact on 08/15/2025.